β-catenin-IN-2 |
| Katalog-Nr.GC62432 |
β-Catenin-IN-2 ist ein starker β-Catenin-Inhibitor, Verbindung H1B1, extrahiert aus dem Patent US20150374662A1. β-catenin-IN-2 kann fÜr die Untersuchung von Darmkrebs verwendet werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1458664-10-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer[1].
β-catenin-IN-2 (10-40 μM) suppresses the transcriptional activity of the β-catenin/Tcf-4 in a dose-dependent manner in HCT116 cells[1].
[1]. Ann Marie Bode, et al. Inhibitors of beta-catenin in treatment of colorectal cancer. Patent US20150374662A1.
Average Rating: 5 (Based on Reviews and 3 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *